Rapport Therapeutics, Inc. Common Stock

NASDAQ: RAPP · Healthcare · Biotechnology

PublicHQ Boston, DECIK 0002012593Reports USD

#1 of 1,394 Healthcare companies by revenue

EA Score

——

FH 74DQ —GM —SS 48

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ listing tenure, Piotroski F

Methodology →

Revenue TTM

$20.0M

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$111.5M

Employees

Market cap

$1.4B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$111.5M-$111.5M2025

Operating income-$125.1M-$125.1M2025

Total assets$512.4M$512.4M2025

Liabilities$27.8M$27.8M2025

Equity$484.7M$484.7M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Rapport Therapeutics, Inc. Common Stock earned -$111.5M in FY2025 net income.

Peers · Healthcare

Xeris Biopharma Holdings, Inc.65B Inhibrx Biosciences Inc.28D Integra LifeSciences Holdings Corporation67B MannKind Corporation69B

Key facts

CEOAbraham N. Ceesay

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, DE

ExchangeNASDAQ: RAPP

Employees69

IPO date2024-06-07

Latest filings

8-K2026-06-10 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-23 8-K2026-04-21 8-K2026-03-10 10-K2026-03-10 8-K2026-01-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.